Novo Integrated Sciences Corp - NVOS Enterprise Value to EBITDA Ratio
Novo Integrated Sciences (NVOS) is pursuing aggressive growth through acquisitions, yet a lack of funds is forcing the business to develop organically. The price indicator on the chart shows an EV/EBITDA of , highlighting the status of a brand that combines science and therapy to improve treatment accessibility. Nevertheless, a fragmented structure and reliance on new acquisitions create significant liquidity risks and complexities in executing the expansion strategy.
Novo Integrated Sciences Inc (NVOS) - metric breakdowns and financial figures
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Novo Integrated Sciences|NVOS - Long-Term Debt to Equity|Short-Term Debt to Equity novointegrated.com|NVOS - Company Cumulative Debt|Debt to Book Value Novo Integrated Sciences Inc|NVOS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Novo Integrated Sciences|Quick Liquidity novointegrated.com
- business earnings and investment ratios data:
NVOS - Company Profit|Future Profit Novo Integrated Sciences|NVOS - Market Price to Net Income Ratio|Forward P/E Multiple Novo Integrated Sciences Corp|NVOS - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Novo Integrated Sciences, Inc.|NVOS - Operating profit before depreciation charges|Earnings per share for the last twelve months Novo Integrated Sciences|NVOS - Earnings per share for the trailing year|Quarterly EPS earnings growth novointegrated.com|NVOS - Earnings growth in current year|Expected earnings per share growth for next year Novo Integrated Sciences
- sales and revenue indicators:
Initial company analysis:Novo Integrated Sciences (NVOS)
The multiple compares the total enterprise value, including net debt, to its operating profit before depreciation and amortization, determining the payback period of the assets. An investor diagnoses undervaluation through low values, although a prolonged decline indicates a systemic crisis. When analyzing business valuation via EV/EBITDA trends, it should be noted that the lack of stable margins at Novo Integrated Sciences (NVOS) renders this indicator volatile and speculative.
Key competitors
HCA Healthcare - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio THC (Tenet Healthcare Corporation)|Fresenius Medical Care - EV/EBITDA Multiple|Solventum Corp - Enterprise Value to Operating Income Before Depreciation Ratio|Encompass Health (EHC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation UHS|Enterprise Value to EBITDA Ratio DVA|EV/EBITDA Multiple RadNet, Inc.|Enterprise Value to EBITDA Ratio OPCH (Option Care Health)|SGRY (Surgery Partners) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Premier Health PINC|America's Best Contacts & Eyeglasses (EYE) - Company Value to EBITDA|PGNY: Enterprise Value to EBITDA Ratio|ARDT (Ardent Health Partners) - Enterprise Value to Operating Income Before Depreciation|SEM (Select Medical Holdings) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation ASTH|Enterprise Value to EBITDA Ratio MD|USPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization The Pennant Group (PNTG)|ORGO - Company Value to EBITDA|EV/EBITDA Multiple NUTX (nutexhealth.com)|EV/EBITDA Multiple Auna S.A. AUNA|SBC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Evolus, Inc. (EOLS) - Enterprise Value to EBITDA Ratio|CYH: EV/EBITDA Multiple|The Beauty Health Company - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio MDWD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BTMD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization The Joint Corporation (JYNT)|DocGo, Inc (DCGO) - Enterprise Value to EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation Ratio P3 Health (PIII)|Enterprise Value to Operating Income Before Depreciation Ratio GANX (Gain Therapeutics)|EUDA Health Holdings - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Basel Medical Group Ltd (BMGL)|CLGN: EV/EBITDA Multiple|CUPR - Total Company Value to Operating Income Before Depreciation Ratio|CCM (Concord Medical Services Holdings) - EV/EBITDA Multiple|Company Value to EBITDA ashs.com AMS|Enterprise Value to EBITDA Ratio MRM (MEDIROM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ALBT (Avalon GloboCare Corp.)|DIH Group - Enterprise Value to EBITDA Ratio|Carmell Corp (XAGE) - Company Value to EBITDA|newgenivf.com - EV/EBITDA Multiple|Company Value to EBITDA atipt.com|CMAX (CareMax, Inc.) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Kindly MD (KDLY)|MODV (ModivCare Inc) - EV/EBITDA Multiple|sunlinkhealth.com (SSY) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BACK (IMAC Regeneration Centers)
